Cargando…

Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials

Patients receive dual antiplatelet therapy (DAPT) for 6–12 months after drug-eluting stents (DES) implantation. The efficacy and safety of prolonged DAPT has been questioned. Therefore, we performed a meta-analysis on randomised trials comparing different DAPT durations. Literature was searched on t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsoi, Man-Fung, Cheung, Ching-Lung, Cheung, Tommy Tsang, Wong, Ian Chi-Kei, Kumana, Cyrus Rustam, Tse, Hung-Fat, Cheung, Bernard Man-Yung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538605/ https://www.ncbi.nlm.nih.gov/pubmed/26278959 http://dx.doi.org/10.1038/srep13204

Ejemplares similares

Blood lead level and risk of hypertension in the United States National Health and Nutrition Examination Survey 1999–2016
por: Tsoi, Man Fung, et al.
Publicado: (2021)

Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
por: Shen, Ying, et al.
Publicado: (2015)

Is the Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents the Longer the Better?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016
por: Tsoi, Man Fung, et al.
Publicado: (2020)

Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?
por: Chang, Mineok, et al.
Publicado: (2014)

Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016
por: Lee, Chun-On, et al.
Publicado: (2021)

Prevalence of Childhood Obesity in the United States 1999 - 2018: A 20-Year Analysis
por: Li, Hang Long, et al.
Publicado: (2021)

Prevalence of Childhood Obesity in the United States in 1999–2018: A 20-Year Analysis
por: Tsoi, Man-Fung, et al.
Publicado: (2022)

One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent
por: Tam, Chor Cheung, et al.
Publicado: (2017)

Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis
por: Gajulapalli, Rama Dilip, et al.
Publicado: (2017)

Influence of dual antiplatelet therapy duration on neointimal condition after second-generation drug-eluting stent implantation
por: Goryo, Yutaka, et al.
Publicado: (2021)

Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
por: Benezet-Mazuecos, Juan, et al.
Publicado: (2007)

Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
por: Jhang, Kai-Ming, et al.
Publicado: (2015)

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial
por: Natsuaki, Masahiro, et al.
Publicado: (2015)

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
por: Tam, Chor-Cheung, et al.
Publicado: (2022)

Managing blood pressure control in Asian patients: safety and efficacy of losartan
por: Cheung, Tommy Tsang, et al.
Publicado: (2014)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-Dragon Registry)
por: Januszek, Rafał, et al.
Publicado: (2022)

Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials
por: Rozemeijer, R., et al.
Publicado: (2018)

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
por: Yin, Shang-He-Lin, et al.
Publicado: (2019)

Duration of dual antiplatelet therapy in patients with acute coronary syndrome undergoing drug-eluting stent implantation: A meta-analysis
por: Geng, Xue, et al.
Publicado: (2020)

Use of ticagrelor and the risks of pneumonia and pneumonia-specific death in patients with non-acute coronary syndrome conditions: a population-based cohort study
por: Feng, Qi, et al.
Publicado: (2021)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
por: Kwok, Chun Shing, et al.
Publicado: (2014)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Publicado: (2016)

Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials
por: Barbarawi, Mahmoud, et al.
Publicado: (2019)

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
por: Fei, Yue, et al.
Publicado: (2019)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021)

Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice
por: Cho, Min Soo, et al.
Publicado: (2017)

One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation
por: Natsuaki, Masahiro, et al.
Publicado: (2020)

Perioperative management of antiplatelet therapy in patients with drug-eluting stents
por: Dimitrova, G, et al.
Publicado: (2012)

Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients
por: Chan, Pak-Hei, et al.
Publicado: (2013)

Simultaneous Thrombosis of Two Drug-Eluting Stents After Discontinuation of Dual Antiplatelet Therapy for a Day
por: Chen, Hung Yi
Publicado: (2012)

Very Late Thrombosis of a Drug-Eluting Stent After Discontinuation of Dual Antiplatelet Therapy in a Patient Treated With Both Drug-Eluting and Bare-Metal Stents
por: Kim, Sung Soo, et al.
Publicado: (2009)

Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials
por: Lin, Bei-you, et al.
Publicado: (2019)

Efficacy and safety of short-term (≤6 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials
por: Xiang, Chun-Lin, et al.
Publicado: (2017)

Long‐Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second‐Generation Drug‐Eluting Stents: The Veterans Affairs Extended DAPT Study
por: Kinlay, Scott, et al.
Publicado: (2023)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation
por: Voudris, Vassilis, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8gcgsqomvbv835lpam79plj4l2